Intranasal administration of liposomes displaying SARS-CoV-2 antigen induces mucosal immunity MDPIOpenAccess UBuffalo SARSCoV2 COVID19 Coronavirus MucosalImmunity
By Tarun Sai LomteSep 14 2022Reviewed by Aimee Molineux A recent study published in Pathogens reported that an intranasal severe acute respiratory syndrome coronavirus 2 vaccine induced mucosal immune responses in mice.
Previously, the authors described liposomes comprising cobalt porphyrin phospholipids . CoPoP liposomes could be formulated with lipid adjuvants such as 3D6A-PHAD. These liposomes could be used to transform soluble antigens into antigenic particles and induce robust immune responses. Besides, these liposomes allow the binding of His-tagged peptides/proteins due to the interactions between cobalt and the His-tag.
Lung homogenates were collected 28 days after immunization. I.M. immunization failed to induce detectable anti-RBD IgA titers in the lungs, whereas I.N. immunization elicited robust IgA titers. However, anti-RBD IgG responses in the lungs were evident with either mode of vaccination. Notably, I.M. immunization induced a significantly stronger serum IgG response than I.N. immunization.
Furthermore, the authors investigated whether the administration of CP/RBD liposomes resulted in their uptake by immune cells in the lungs. To this end, they engineered a Co-free PoP as a fluorescent tracer. The uptake of the CPP/RBD liposomes by antigen-presenting cells was evaluated 24 hours after administration.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancyIn an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).
Read more »
BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptomsResearchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.
Read more »
Small molecule inhibitor found to be effective against SARS-CoV-2 variantsIn a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).
Read more »
Parenteral-prime mucosal boost an effective strategy to protect against SARS-CoV-2In a recent study published in the journal eBioMedicine, researchers in Denmark and Sweden administered a cationic liposome-adjuvanted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit vaccine as a subcutaneous (s.c.) prime-intranasal (i.n.) boost strategy to elicit mucosal immune responses among SARS-CoV-2-infected Syrian hamsters.
Read more »
What is the risk of SARS-CoV-2 infection among gout patients?What is the risk of SARS-CoV-2 infection among gout patients? SARSCoV2 COVID19 Coronavirus Gout GoutPatients
Read more »
Transplacental passage of specific IgG in maternal SARS-CoV-2 infectionTransplacental passage of specific IgG in maternal SARS-CoV-2 infection infection pregnancy COVID19 coronavirus covid SARSCoV2 antibody maternal disease
Read more »